Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization
SOHM Inc. (OTC:SHMN) has appointed Dr. Leonardo Mirandola as Advisory Board Member to advance its CAR-T cell projects toward clinical trials. Dr. Mirandola, a biopharma scientist with over a decade of experience in oncology and cell therapy, previously served as CSO and Interim COO at Kiromic Biopharma, where he developed therapies including an FDA Fast-Track-designated allogeneic gamma-delta T-cell therapy for Stage 4 non-small cell lung cancer.
SOHM is leveraging its proprietary gene editing platform, ABBIE, to enhance CAR-T cell therapy commercialization. ABBIE offers advantages over traditional viral-based or CRISPR systems, including cost-efficiency, reduced manufacturing complexity, and fewer regulatory hurdles. The company aims to improve production timelines, genetic payload fidelity, and therapeutic window accessibility.
SOHM Inc. (OTC:SHMN) ha nominato Dr. Leonardo Mirandola come membro del Consiglio Consultivo per far avanzare i suoi progetti di cellule CAR-T verso le sperimentazioni cliniche. Il Dr. Mirandola, scienziato biopharma con oltre un decennio di esperienza in oncologia e terapia cellulare, ha precedentemente ricoperto il ruolo di CSO e COO ad interim presso Kiromic Biopharma, dove ha sviluppato terapie tra cui una terapia allogenica con cellule T gamma-delta designata dalla FDA come Fast-Track per il carcinoma polmonare non a piccole cellule in stadio 4.
SOHM sta sfruttando la sua piattaforma proprietaria di editing genetico, ABBIE, per potenziare la commercializzazione della terapia con cellule CAR-T. ABBIE offre vantaggi rispetto ai tradizionali sistemi virali o CRISPR, tra cui maggiore efficienza nei costi, minore complessità produttiva e meno ostacoli regolatori. L'azienda mira a migliorare i tempi di produzione, la fedeltà del carico genetico e l'accessibilità della finestra terapeutica.
SOHM Inc. (OTC:SHMN) ha nombrado a Dr. Leonardo Mirandola como miembro del Consejo Asesor para impulsar sus proyectos de células CAR-T hacia ensayos clínicos. El Dr. Mirandola, científico biopharma con más de una década de experiencia en oncología y terapia celular, previamente se desempeñó como CSO y COO interino en Kiromic Biopharma, donde desarrolló terapias, incluyendo una terapia alogénica de células T gamma-delta designada por la FDA con Fast-Track para cáncer de pulmón no microcítico en estadio 4.
SOHM está aprovechando su plataforma propietaria de edición genética, ABBIE, para mejorar la comercialización de la terapia con células CAR-T. ABBIE ofrece ventajas sobre los sistemas tradicionales basados en virus o CRISPR, incluyendo eficiencia en costos, menor complejidad en la fabricación y menos obstáculos regulatorios. La compañía busca mejorar los tiempos de producción, la fidelidad del material genético y la accesibilidad de la ventana terapéutica.
SOHM Inc. (OTC:SHMN)는 CAR-T 세포 프로젝트를 임상 시험 단계로 진전시키기 위해 레오나르도 미란돌라 박사를 자문위원으로 임명했습니다. 미란돌라 박사는 10년 이상의 종양학 및 세포 치료 경험을 가진 바이오제약 과학자로, 이전에 Kiromic Biopharma에서 CSO 및 임시 COO로 재직하며 FDA의 패스트트랙 지정을 받은 4기 비소세포 폐암 치료용 동종 감마-델타 T세포 치료제를 포함한 치료법을 개발했습니다.
SOHM은 자체 유전자 편집 플랫폼 ABBIE를 활용하여 CAR-T 세포 치료제 상용화를 강화하고 있습니다. ABBIE는 기존의 바이러스 기반 또는 CRISPR 시스템에 비해 비용 효율성, 제조 복잡성 감소, 규제 장벽 완화 등의 이점을 제공합니다. 회사는 생산 기간, 유전적 적재 정확성, 치료적 적용 범위 개선을 목표로 하고 있습니다.
SOHM Inc. (OTC:SHMN) a nommé Dr Leonardo Mirandola membre du conseil consultatif afin de faire progresser ses projets de cellules CAR-T vers des essais cliniques. Le Dr Mirandola, scientifique en biopharmacie avec plus de dix ans d'expérience en oncologie et thérapie cellulaire, a précédemment occupé les postes de CSO et COO intérimaire chez Kiromic Biopharma, où il a développé des thérapies, dont une thérapie allogénique par cellules T gamma-delta bénéficiant d'une désignation Fast-Track de la FDA pour le cancer du poumon non à petites cellules de stade 4.
SOHM exploite sa plateforme propriétaire d'édition génétique, ABBIE, pour améliorer la commercialisation de la thérapie par cellules CAR-T. ABBIE présente des avantages par rapport aux systèmes traditionnels à base virale ou CRISPR, notamment en termes de coût, de complexité de fabrication réduite et de moindres obstacles réglementaires. L'entreprise vise à améliorer les délais de production, la fidélité du chargement génétique et l'accessibilité de la fenêtre thérapeutique.
SOHM Inc. (OTC:SHMN) hat Dr. Leonardo Mirandola als Mitglied des Beirats berufen, um die CAR-T-Zellprojekte des Unternehmens in Richtung klinischer Studien voranzutreiben. Dr. Mirandola ist ein Biopharma-Wissenschaftler mit über einem Jahrzehnt Erfahrung in Onkologie und Zelltherapie. Zuvor war er CSO und Interim-COO bei Kiromic Biopharma, wo er Therapien entwickelte, darunter eine von der FDA als Fast-Track eingestufte allogene Gamma-Delta-T-Zelltherapie für Lungenkrebs im Stadium 4 (nicht-kleinzellig).
SOHM nutzt seine proprietäre Gen-Editing-Plattform ABBIE, um die Kommerzialisierung der CAR-T-Zelltherapie zu verbessern. ABBIE bietet Vorteile gegenüber herkömmlichen viralen oder CRISPR-basierten Systemen, darunter Kosteneffizienz, geringere Herstellungskomplexität und weniger regulatorische Hürden. Das Unternehmen strebt an, Produktionszeiten, genetische Ladungsgenauigkeit und den therapeutischen Zugang zu optimieren.
- Appointment of highly experienced Dr. Mirandola with proven track record in clinical translation
- Dr. Mirandola's previous success with FDA Fast-Track-designated therapy development
- Proprietary ABBIE platform offers cost-efficient advantages over traditional gene-editing systems
- Potential for streamlined production and broader therapeutic applications
- CAR-T cell projects still in pre-clinical phase
- No timeline provided for clinical trials initiation
- Uncertain regulatory pathway ahead
CHINO HILLS, CA / ACCESS Newswire / May 2, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, proudly announces Dr. Leonardo Mirandola joined the Company as Advisory Board Member. Dr. Mirandola, a biopharma scientist with over a decade of experience in oncology and cell therapy, will spearhead the company's initiatives to advance its CAR-T cell projects toward clinical trials.
Dr. Mirandola brings a wealth of expertise in operational management, R&D, and clinical development, with a proven track record in transforming innovative scientific breakthroughs into viable treatment options. He holds a Ph.D. and a Master's degree from the University of Milano, Italy.
"Dr. Mirandola's extensive background in cell therapy and his remarkable success in clinical translation make him an invaluable addition to our team," said David Aguilar of SOHM Inc. "His leadership will be instrumental as we push the boundaries of CAR-T cell production and therapy and strive to bring new treatment options to those battling cancer."
Before joining SOHM Inc., Dr. Mirandola served as Chief Scientific Officer and Interim Chief Operations Officer at Kiromic Biopharma, where he played a pivotal role in developing and overseeing clinical operations for various groundbreaking therapies. His contributions led to the advancement of an autologous dendritic cell therapeutic vaccine for solid tumors and an allogeneic gamma-delta T-cell therapy, which has received Fast-Track-designation by the FDA and showed positive results in Phase 1 trials for patients with Stage 4 non-small cell lung cancer.
Dr. Mirandola has a remarkable record of securing patents for novel manufacturing techniques and AI-driven target discovery processes, which have significantly advanced the understanding and development of cell therapies. His leadership in establishing cGMP-compliant manufacturing processes will be critical as SOHM Inc. prepares its CAR-T cell projects for rigorous clinical evaluation.
"I am excited to join SOHM Inc. and collaborate with such a talented team dedicated to making a difference in the lives of cancer patients," said Dr. Mirandola.
SOHM, Inc. is harnessing the power of ABBIE, its proprietary gene editing platform, to accelerate and enhance the commercialization of CAR-T cell therapies. Unlike traditional viral-based or CRISPR systems, ABBIE offers a cost-efficient editing approach that significantly reduces manufacturing complexity and regulatory hurdles. By integrating ABBIE into its CAR-T development pipeline, SOHM aims to streamline production timelines, improve genetic payload fidelity, and broaden the therapeutic window - ultimately making advanced cell therapies more accessible and scalable for a wider range of cancer patients.
For further information on SOHM Inc. and its latest advancements in biotechnology, please visit www.sohm.com (http://www.sohm.com).
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on ACCESS Newswire
FAQ
Who is Dr. Leonardo Mirandola and what is his role at SOHM (SHMN)?
What is SOHM's ABBIE platform and how does it differ from traditional gene-editing systems?
What are Dr. Mirandola's previous achievements in cell therapy development?
How will SOHM's CAR-T cell therapy development benefit from the ABBIE platform?
